Salesforce Inc.

01/15/2026 | Press release | Distributed by Public on 01/15/2026 07:28

Adamed Selects Salesforce Agentforce Life Sciences for Customer Engagement to Power Commercial Growth in Spain

Adamed Laboratorios, a leading Spanish pharmaceutical company specializing in the development and distribution of prescription drugs, will help modernize its commercial operations and deepen customer relationships with Salesforce's Agentforce Life Sciences for Customer Engagement. Adamed will unify critical commercial processes; support sophisticated customer engagement across multiple channels; and achieve a comprehensive, 360-degree view of its customers, all working to further its mission of building future commercial excellence.

The selection of Agentforce Life Sciences for Customer Engagement by Adamed is a powerful validation of our unified platform strategy.

Frank Defesche, SVP and GM at Agentforce Life Sciences

Salesforce was specifically chosen for its unique ability to deliver:

  • Unified Customer Views: Adamed will create a complete, holistic picture of every professional, hospital, and pharmacy account using Data 360 and MuleSoft, consolidating all interactions - including visits, events, and orders - and ensuring trusted customer data via real-time MuleSoft integrations to systems such as IQVIA OneKey.
  • Enhanced Field Enablement: Adamed will enhance crucial field activities, including call reporting, cycle planning, and multimedia content presentation, enabled by Agentforce to deliver next best actions and automated insights, helping improve productivity.
  • Omni-Channel Order and Events Management: Adamed will streamline order and events management with approval flows and marketing campaigns using Agentforce Marketing across channels like email and SMS and by using Tableau to provide deep, real-time insights into delivery status and pricing recommendations.
  • Offline Mobile Functionality: Adamed will optimize its account and visit management processes and allow commercial teams to deliver targeted, high-value engagements with healthcare professionals (HCPs) and partners using robust desktop and tablet capabilities for on-the-go productivity for field and account teams.

"Modern life sciences companies need agile technology that can adapt to global scale while meeting local market demands and compliance requirements," said Bernardo de Rafael, GM at Adamed Laboratorios. "Agentforce Life Sciences for Customer Engagement provides the critical mobile, compliance support, and e-detailing features we need to empower our teams in Spain and set the standard for customer relationship management across our organization. This investment is key to executing our commercial strategy and ensuring better access to our portfolio of medicines."

"The selection of Agentforce Life Sciences for Customer Engagement by Adamed is a powerful validation of our unified platform strategy," said Frank Defesche, SVP and GM at Agentforce Life Sciences. "Companies like Adamed recognize that adopting new AI innovations and embracing a true 360-degree view of the customer - powered by Agentforce - is critical for commercial growth. This foundational partnership in Spain not only accelerates Adamed's immediate operational agility but also sets the standard for a scalable, international rollout that will transform how they engage with customers across the globe."

As part of the company's development strategy, Adamed Laboratorios' implementation will be led by Izertis, a trusted Salesforce partner, bringing its expertise in life sciences digital transformation to ensure successful deployment and adoption.

Learn more:

About Adamed

Adamed Laboratorios is the Spanish branch of Adamed Pharma S.A., an international Polish pharmaceutical and biotechnology company specializing in innovative therapeutic solutions. The company focuses on research and development (R&D) to address key challenges in modern medicine, particularly in the areas of central nervous system disorders, oncology, and cardiovascular risks.

Salesforce Inc. published this content on January 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 15, 2026 at 13:28 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]